FDA Approves Eli Lilly’s New Weight Loss Drug
The Food and Drug Administration (FDA) announced on Wednesday the approval of Foundayo, a new weight loss medication developed by Eli Lilly. This marks a significant addition to the growing market for weight loss therapies.
Details on Foundayo’s Availability
Foundayo is the second oral GLP-1 medication to receive approval in recent months, following the launch of Novo Nordisk’s Wegovy in December. The new medication is offered in six different doses, with patients typically starting on the lowest dosage and gradually increasing to mitigate side effects. Unlike Wegovy, which requires administration on an empty stomach every morning, Foundayo can be taken at any time of the day without dietary restrictions.
Cost and Insurance Coverage for Patients
For those managing costs out-of-pocket, the lowest dose of Foundayo is priced around $149 per month, while higher doses may approach $399. This pricing is comparable to that of Wegovy’s tablets. It’s still uncertain how many private insurance providers will offer coverage for this new drug. Additionally, under policies established during the Trump administration, Medicare could potentially begin providing coverage for eligible patients this summer, with out-of-pocket expenses potentially as low as $50 per month.
Significance of the Oral Delivery Format
Eli Lilly’s CEO, Dave Ricks, emphasized the importance of this advancement, stating that an easy-to-take oral tablet makes it more convenient for patients to incorporate into their daily routines. “Simply add it to your pill case in the morning,” he noted. This development comes amid a broader expansion of the GLP-1 market, characterized by new products offering enhanced weight loss results, varied formulations, and competitive pricing.
Future Developments in Weight Loss Medications
Eli Lilly is also working on another GLP-1 drug, identified as letaltortide, which has demonstrated greater weight loss effectiveness in clinical trials compared to existing treatments. However, it is important to note that oral formulations such as Foundayo typically yield less weight loss than injectable options, which may affect their appeal to prospective patients.
Comparative Weight Loss Data
Results from a Phase 3 clinical trial indicate that patients taking Foundayo experienced an average weight loss of 12.4% after 72 weeks at the highest dose. While comparable to Wegovy, this figure is lower than the results observed with injectable versions like Wegovy and Zepbound. Nevertheless, these figures are not directly comparable, as the drugs have not undergone head-to-head clinical tests.
Professional Perspectives on Effectiveness
Dr. Jodi Duchey, an endocrinologist and obesity specialist from Harvard Medical School, expressed concerns about the effectiveness of the oral medication compared to injectables, noting that patients transitioning from Wegovy injections often report diminished weight loss. “While the current data show 12% weight loss, it falls short compared to expectations from Wegovy or Zepbound,” Duchey commented. Ricks acknowledged that while Zepbound may be more effective, he believes Foundayo offers unique advantages for patients seeking a less invasive option.
Strong Demand for Weight Loss Solutions
Consumer interest in weight loss medications remains robust, as highlighted by Novo Nordisk’s report in February that over 170,000 individuals had used Wegovy tablets since its introduction. Dr. Duchey noted that Foundayo could serve as a valuable maintenance option for those looking to sustain weight loss following injectable therapy, especially for patients who experience discomfort with injections.
Potential Side Effects of Foundayo
Eli Lilly reported that the side effects associated with Foundayo are similar to those experienced with injectable GLP-1 drugs, with gastrointestinal issues such as nausea, constipation, and diarrhea being the most prevalent complaints among users.
